Luiz Eduardo Baggio Savio1, Paola de Andrade Mello2, Vanessa R Figliuolo3, Thiago F de Avelar Almeida3, Patrícia T Santana3, Suellen D S Oliveira4, Claudia L M Silva5, Linda Feldbrügge6, Eva Csizmadia6, Richard D Minshall7, Maria Serena Longhi6, Yan Wu6, Simon C Robson8, Robson Coutinho-Silva9. 1. Laboratory of Immunophysiology, Biophysics Institute Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA. 2. Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA; Faculty of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. 3. Laboratory of Immunophysiology, Biophysics Institute Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 4. Laboratory of Immunophysiology, Biophysics Institute Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Departments of Anesthesiology and Pharmacology, University of Illinois, Chicago, IL, USA. 5. Laboratory of Molecular and Biochemical Pharmacology, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. 6. Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA. 7. Departments of Anesthesiology and Pharmacology, University of Illinois, Chicago, IL, USA. 8. Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, USA. Electronic address: srobson@bidmc.harvard.edu. 9. Laboratory of Immunophysiology, Biophysics Institute Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil. Electronic address: rcsilva@biof.ufrj.br.
Abstract
BACKGROUND & AIMS: The severity of sepsis can be linked to excessive inflammatory responses resulting in hepatic injury. P2X7 receptor activation by extracellular ATP (eATP) exacerbates inflammation by augmenting cytokine production; while CD39 (ENTPD1) scavenges eATP to generate adenosine, thereby limiting P2X7 activation and resulting in A2A receptor stimulation. We aim to determine how the functional interaction of P2X7 receptor and CD39 control the macrophage response, and consequently impact on sepsis and liver injury. METHODS: Sepsis was induced by cecal ligation and puncture in C57BL/6 wild-type (WT) and CD39-/- mice. Several in vitro assays were performed using peritoneal or bone marrow derived macrophages to determine CD39 ectonucleotidase activity and its role in sepsis-induced liver injury. RESULTS: CD39 expression in macrophages limits ATP-P2X7 receptor pro-inflammatory signaling. P2X7 receptor paradoxically boosts CD39 activity. Inhibition and/or deletion of P2X7 receptor in LPS-primed macrophages attenuates cytokine production and inflammatory signaling as well as preventing ATP-induced increases in CD39 activity. Septic CD39-/- mice exhibit higher levels of inflammatory cytokines and show more pronounced liver injury than WT mice. Pharmacological P2X7 blockade largely prevents tissue damage, cell apoptosis, cytokine production, and the activation of inflammatory signaling pathways in the liver from septic WT, while only attenuating these outcomes in CD39-/- mice. Furthermore, the combination of P2X7 blockade with adenosine A2A receptor stimulation completely inhibits cytokine production, the activation of inflammatory signaling pathways, and protects septic CD39-/- mice against liver injury. CONCLUSIONS: CD39 attenuates sepsis-associated liver injury by scavenging eATP and ultimately generating adenosine. We propose boosting of CD39 would suppress P2X7 responses and trigger adenosinergic signaling to limit systemic inflammation and restore liver homeostasis during the acute phase of sepsis. Lay summary: CD39 expression in macrophages limits P2X7-mediated pro-inflammatory responses, scavenging extracellular ATP and ultimately generating adenosine. CD39 genetic deletion exacerbates sepsis-induced experimental liver injury. Combinations of a P2X7 antagonist and adenosine A2A receptor agonist are hepatoprotective during the acute phase of abdominal sepsis.
BACKGROUND & AIMS: The severity of sepsis can be linked to excessive inflammatory responses resulting in hepatic injury. P2X7 receptor activation by extracellular ATP (eATP) exacerbates inflammation by augmenting cytokine production; while CD39 (ENTPD1) scavenges eATP to generate adenosine, thereby limiting P2X7 activation and resulting in A2A receptor stimulation. We aim to determine how the functional interaction of P2X7 receptor and CD39 control the macrophage response, and consequently impact on sepsis and liver injury. METHODS:Sepsis was induced by cecal ligation and puncture in C57BL/6 wild-type (WT) and CD39-/- mice. Several in vitro assays were performed using peritoneal or bone marrow derived macrophages to determine CD39 ectonucleotidase activity and its role in sepsis-induced liver injury. RESULTS:CD39 expression in macrophages limits ATP-P2X7 receptor pro-inflammatory signaling. P2X7 receptor paradoxically boosts CD39 activity. Inhibition and/or deletion of P2X7 receptor in LPS-primed macrophages attenuates cytokine production and inflammatory signaling as well as preventing ATP-induced increases in CD39 activity. Septic CD39-/- mice exhibit higher levels of inflammatory cytokines and show more pronounced liver injury than WT mice. Pharmacological P2X7 blockade largely prevents tissue damage, cell apoptosis, cytokine production, and the activation of inflammatory signaling pathways in the liver from septic WT, while only attenuating these outcomes in CD39-/- mice. Furthermore, the combination of P2X7 blockade with adenosine A2A receptor stimulation completely inhibits cytokine production, the activation of inflammatory signaling pathways, and protects septic CD39-/- mice against liver injury. CONCLUSIONS:CD39 attenuates sepsis-associated liver injury by scavenging eATP and ultimately generating adenosine. We propose boosting of CD39 would suppress P2X7 responses and trigger adenosinergic signaling to limit systemic inflammation and restore liver homeostasis during the acute phase of sepsis. Lay summary: CD39 expression in macrophages limits P2X7-mediated pro-inflammatory responses, scavenging extracellular ATP and ultimately generating adenosine. CD39 genetic deletion exacerbates sepsis-induced experimental liver injury. Combinations of a P2X7 antagonist and adenosine A2A receptor agonist are hepatoprotective during the acute phase of abdominal sepsis.
Authors: György Haskó; Balázs Csóka; Balázs Koscsó; Rachna Chandra; Pál Pacher; Linda F Thompson; Edwin A Deitch; Zoltán Spolarics; László Virág; Pál Gergely; Rolando H Rolandelli; Zoltán H Németh Journal: J Immunol Date: 2011-09-14 Impact factor: 5.422
Authors: Davide Ferrari; Cinzia Pizzirani; Elena Adinolfi; Roberto M Lemoli; Antonio Curti; Marco Idzko; Elisabeth Panther; Francesco Di Virgilio Journal: J Immunol Date: 2006-04-01 Impact factor: 5.422
Authors: M Remy; S Thaler; R G Schumann; C A May; M Fiedorowicz; F Schuettauf; M Grüterich; S G Priglinger; M M Nentwich; A Kampik; C Haritoglou Journal: Br J Ophthalmol Date: 2008-08 Impact factor: 4.638
Authors: Miguel Meriño; Sebastián San Martín; Pedro Sandaña; Kurt Herlitz; Claudio Aguayo; Alejandro Godoy; Pablo Torres-Vergara; Marcelo Gonzalez; Felipe Troncoso; Jesenia Acurio; Carlos Escudero Journal: Purinergic Signal Date: 2020-08-17 Impact factor: 3.765
Authors: Luiz Eduardo Baggio Savio; Paola de Andrade Mello; Stephanie Alexia Cristina Silva Santos; Júlia Costa de Sousa; Suellen D S Oliveira; Richard D Minshall; Eleonora Kurtenbach; Yan Wu; Maria Serena Longhi; Simon C Robson; Robson Coutinho-Silva Journal: J Cell Sci Date: 2020-03-06 Impact factor: 5.285
Authors: Robson Coutinho-Silva; Luiz Eduardo Baggio Savio; Maria Luciana Larrouyet-Sarto; Augusto Shuiti Tamura; Vinícius Santos Alves; Patrícia T Santana; Roberta Ciarlini-Magalhães; Thuany Prado Rangel; Cassiana Siebert; Josiane R Hartwig; Tiago Marcon Dos Santos; Angela T S Wyse; Christina Maeda Takiya Journal: Purinergic Signal Date: 2020-10-22 Impact factor: 3.765